[go: up one dir, main page]

WO2002018647A1 - Haplotypes du gene gng7 - Google Patents

Haplotypes du gene gng7 Download PDF

Info

Publication number
WO2002018647A1
WO2002018647A1 PCT/US2001/026279 US0126279W WO0218647A1 WO 2002018647 A1 WO2002018647 A1 WO 2002018647A1 US 0126279 W US0126279 W US 0126279W WO 0218647 A1 WO0218647 A1 WO 0218647A1
Authority
WO
WIPO (PCT)
Prior art keywords
gng7
haplotype
gene
seq
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/026279
Other languages
English (en)
Inventor
Kevin Finkel
Stefanie E. Kliem
Beena Koshy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cogenics Inc
Original Assignee
Genaissance Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaissance Pharmaceuticals Inc filed Critical Genaissance Pharmaceuticals Inc
Priority to AU2001286644A priority Critical patent/AU2001286644A1/en
Publication of WO2002018647A1 publication Critical patent/WO2002018647A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Definitions

  • a particularly preferred polymorphic variant is an isogene of the GNG7 gene.
  • a GNG7 isogene of the invention comprises guanine or thymine at PSI, adenine or guanine at PS2 and guanine or adenine at PS3.
  • the invention also provides a collection of GNG7 isogenes, referred to herein as a GNG7 genome anthology.
  • Polynucleotides complementary to these GNG7 genomic DNA variants are also provided by the invention. It is believed that polymorphic variants of the GNG7 gene will be useful in studying the expression and function of GNG7, and in expressing GNG7 protein for use in screening for candidate drugs to treat diseases related to GNG7 activity.
  • Full-genotype The unphased 5' to 3 ' sequence of nucleotide pairs found at all polymorphic sites examined herein in a locus on a pair of homologous chromosomes in a single individual.
  • Sub-genotype The unphased 5 ' to 3 ' sequence of nucleotides seen at a subset of the polymorphic sites examined herein in a locus on a pair of homologous chromosomes in a single individual.
  • Polymorphism Database A collection of polymo ⁇ hism data arranged in a systematic or methodical way and capable of being individually accessed by electronic or other means.
  • an oligonucleotide primer may have a non-complementary fragment at its 5 ' end, with the remainder of the primer being complementary to the target region.
  • non-complementary nucleotides may be interspersed into the probe or primer as long as the resulting probe or primer is still capable of specifically hybridizing to the target region.
  • the frequencies of the genotype(s), haplotype(s), or haplotype pair(s) of interest in the reference and trait populations are compared.
  • the frequencies of all genotypes, haplotypes, and/or haplotype pairs observed in the populations are compared. If a particular GNG7 genotype, haplotype, or haplotype pair is more frequent in the trait population than in the reference population at a statistically significant amount, then the trait is predicted to be associated with that GNG7 genotype, haplotype or haplotype pair.
  • Correlations may also be analyzed using analysis of variation (ANOVA) techniques to determine how much of the variation in the clinical data is explained by different subsets of the polymo ⁇ hic sites in the GNG7 gene.
  • ANOVA analysis of variation
  • ANOVA is used to test hypotheses about whether a response variable is caused by or correlated with one or more traits or variables that can be measured (Fisher and vanBelle, supra, Ch. 10).
  • Fragment 1 3296-3314 complement of 3844-3823

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des nouvelles variantes génétiques du gène GNG7 (protéine de liaison nucléotidique à la guanine (protéine G), gamma 7). Elle concerne également plusieurs génotypes, haplotypes et paires d'haplotypes existant dans la population générale des Etats-Unis pour le gène GNG7. L'invention se rapporte en outre à des compositions et à des méthodes destinées à soumettre le gène GNG7 à un haplotypage et/ou à un génotypage chez un individu. Elle porte enfin sur des polynucléotides définis par les haplotypes susmentionnés.
PCT/US2001/026279 2000-08-25 2001-08-23 Haplotypes du gene gng7 Ceased WO2002018647A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001286644A AU2001286644A1 (en) 2000-08-25 2001-08-23 Haplotypes of the gng7 gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22823400P 2000-08-25 2000-08-25
US60/228,234 2000-08-25

Publications (1)

Publication Number Publication Date
WO2002018647A1 true WO2002018647A1 (fr) 2002-03-07

Family

ID=22856342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026279 Ceased WO2002018647A1 (fr) 2000-08-25 2001-08-23 Haplotypes du gene gng7

Country Status (2)

Country Link
AU (1) AU2001286644A1 (fr)
WO (1) WO2002018647A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006934A3 (fr) * 2002-07-10 2004-04-01 Hans Robert Kalbitzer Procede et composes pour modifier la structure tridimensionnelle de proteines gnb

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENCORE [online] NATIONAL LIBRARY OF MEDICINE (BETHESDA, MD, USA); LAMERDIN ET AL.: "Sequence analysis of a 3.5 Mb contig in human 19p13.3 containing a serine protease gene cluster", XP002907034, accession no. STN Database accession no. AC005512 *
HUROWITZ ET AL.: "Genomic characterization of the human heterotrimeric G protein alpha, beta and gamma subunit genes", DNA RES., vol. 7, 2000, pages 111 - 120, XP002907035 *
WATSON ET AL.: "G-protein gamma-7 subunit is selectively expressed in medium-sized neurons and dendrites of the rat neostriatum", JOURNAL OF NEUROSCIENCE RES., vol. 39, 1994, pages 108 - 116, XP002907625 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006934A3 (fr) * 2002-07-10 2004-04-01 Hans Robert Kalbitzer Procede et composes pour modifier la structure tridimensionnelle de proteines gnb

Also Published As

Publication number Publication date
AU2001286644A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
WO2001090122A2 (fr) Haplotypes du gene ctla4
WO2001092582A1 (fr) Haplotypes du gene ube3a
WO2001079229A2 (fr) Haplotypes du gene cxcr4
WO2001079230A2 (fr) Haplotypes du gene ugt1a1
WO2002026764A2 (fr) Haplotypes du gene ccr6
WO2001085998A1 (fr) Haplotypes du gene crybb1
WO2002090512A2 (fr) Haplotypes du gene nnmt
WO2001058914A2 (fr) Haplotypes du gene de l'interleukine 15
WO2001079551A1 (fr) Haplotypes du gene nat1
WO2001079547A1 (fr) Haplotypes du gene scn2b
WO2002018413A2 (fr) Haplotypes du gene scya2
WO2001094376A1 (fr) Haplotypes du gene cfl1
WO2002018647A1 (fr) Haplotypes du gene gng7
WO2002053575A1 (fr) Isogenes cibles de medicaments : polymorphismes dans le gene de la lecithine-cholesterol acyltransferase
WO2001023404A1 (fr) Isogenes cibles de medicaments: polymorphismes dans le gene d'interleukine 4
WO2002020556A2 (fr) Haplotypes du gene gpr68
WO2002016631A1 (fr) Haplotypes du gene ifng
WO2002032930A2 (fr) Haplotypes du gene scya21
WO2002063044A2 (fr) Haplotypes du gene il15
WO2001098315A2 (fr) Haplotypes du gene hmgcl
WO2001087904A2 (fr) Haplotypes du gene gpr4
WO2001079218A2 (fr) Haplotypes du gene calm1
WO2002090378A2 (fr) Haplotypes du gene de ces2
WO2001077126A2 (fr) Haplotypes du gene hsd3b2
WO2001029263A1 (fr) Isogenes cible de medicament: polymorphismes dans le gene 1e du recepteur de 5-hydroxytryptamine (serotonine)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP